Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutatio
Phase 2
Recruiting
- Conditions
- Familial erythromelalgia
- Registration Number
- JPRN-jRCTs071180055
- Lead Sponsor
- Takahashi Kenzo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
1.Older than 15 years
2.A case of erythromelalgia due to SCN9A gene mutation
3.A case who consent to informed consent
Exclusion Criteria
1.A case with severe liver dysfunction(greater than Child-Pug Score C)2.A case with significant ECG abnormality(second-degree atrioventricular block,Brugada symdrome)
3.A case who is considered by a doctor to be inappropriate for administration of lacosamide.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount of change in scoring below 16 weeks after starting lacosamide administration <br>PI-NRS Pain Intensity Numerical Rating Scale
- Secondary Outcome Measures
Name Time Method Amount of change in scoring of PI-NRS and DSIS.<br>Change over time of blood test ( WBC, Hb, PLT, AST, ALT, BUN, Crea, LDH)